Ranitidine hydrochloride stomach specific bouyant microsponge: Preparation, in-vitro characterization, and in-vivo anti-ulcer activity

Development of apigenin loaded gastroretentive microsponge for the targeting of Helicobacter pylori

“…APG's XRD spectrum revealed several distinct, strong peaks at 6.18°, 7.82°, 12.26°, and 17.31°, indicating that the substance is present in crystalline form. At diffraction angles between 5 and 40°, EGT did not exhibit any distinguishing peaks, indicating that they are amorphous in nature ( Jafar et al, 2020 ). All the apigenin's distinctive peaks are present in the physical mixture with very minor variations.…”

“…Microsponge is an advanced gastro-retentive drug delivery system of sponge microparticles consisting of highly pored microspheres and numerous interconnected voids ranging between 5 and 300 μm in diameter ( Jafar et al, 2020 , Chandra et al, 2017 , Singhvi et al, 2019 , Patel et al, 2016 , Arathy and Sunil, 2020 ). Additionally, the microsponge system presents in different formulations including oral and topical forms, providing systemic and local effects ( Arathy and Sunil, 2020 ).…”

Therapeutic Effects Evaluation of Vitamin E Alone and in Combination With Ranitidine in Stress – Induced Gastric Ulcers in Rats

“…It acts as a reversible antagonist of H2 receptors located on the gastric cells. That appears to decrease the impact of gastric offensives such as pepsin and hypersecretion of stomach acid 8 .…”

Development and Evaluation of Oral Sustained-Release Ranitidine Delivery System Based on Bacterial Nanocellulose Material Produced by Komagataeibacter Xylinus

“…RAN is an antisecretory drug with H2 antagonist action useful in treating gastric and duodenal disorders [11][12][13][14][15][16][17][18][19][20]. The adult oral dosage, frequency of RAN is 150 mg twice per d or 300 mg once per d. A conventional dose of 150 mg can inhibit gastric acid secretion up to 5 h but not up to 10 h. An alternative dose of 300 mg leads to plasma fluctuations [18,20,21]. The reason for multiple dosing frequencies or high dose is due to its short biological half-life (2-3 h) and low bioavailability (50 %) [13,15,18,21].…”

“…The adult oral dosage, frequency of RAN is 150 mg twice per d or 300 mg once per d. A conventional dose of 150 mg can inhibit gastric acid secretion up to 5 h but not up to 10 h. An alternative dose of 300 mg leads to plasma fluctuations [18,20,21]. The reason for multiple dosing frequencies or high dose is due to its short biological half-life (2-3 h) and low bioavailability (50 %) [13,15,18,21]. In order to overcome these problems, an attempt was made to develop oral sustained-release drug delivery systems for RAN.…”